TP53 and cancer: Specifically, p53 mutations promote increased mesenchymal-to-epithelial transition (MET) trafficking and signaling, enhancing cell motility and invasiveness, further escalating the aggressive behavior of cancer cells, and contributing to resistance against therapeutic interventions.